Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better